Aravive Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für Aravive zu prognostizieren.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	None
Zuletzt aktualisiert	n/a

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Aravive shares rise after dosing first patient in late-stage ovarian cancer study

Apr 27

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Mar 18

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Feb 09

Aravive: Pipeline-In-A-Pill In Oncology

Dec 28

Aravive (ARAV) Investor Presentation - Slideshow

Dec 04

Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative

Nov 19

Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China

Nov 10

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da Aravive jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ARAV - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
9/30/2023	7	-40	-59	-59	N/A
6/30/2023	9	-77	-69	-69	N/A
3/31/2023	10	-113	-70	-70	N/A
12/31/2022	9	-76	-65	-65	N/A
9/30/2022	9	-60	-59	-59	N/A
6/30/2022	6	-56	-49	-49	N/A
3/31/2022	8	-44	-35	-35	N/A
12/31/2021	7	-39	-32	-32	N/A
9/30/2021	12	-30	-20	-20	N/A
6/30/2021	10	-30	-17	-17	N/A
3/31/2021	6	-28	-18	-18	N/A
12/31/2020	6	-31	-12	-12	N/A
9/30/2020	N/A	-31	-21	-21	N/A
6/30/2020	N/A	-26	-19	-19	N/A
3/31/2020	3	-24	-20	-20	N/A
12/31/2019	5	-18	-17	-17	N/A
9/30/2019	6	-65	-21	-21	N/A
6/30/2019	6	-65	-23	-23	N/A
3/31/2019	3	-72	-23	-23	N/A
12/31/2018	1	-76	-29	-29	N/A
9/30/2018	40	6	-58	-57	N/A
6/30/2018	40	-37	-78	-75	N/A
3/31/2018	40	-64	-94	-90	N/A
12/31/2017	40	-85	-121	-116	N/A
9/30/2017	N/A	-138	-101	-98	N/A
6/30/2017	N/A	-116	N/A	-53	N/A
3/31/2017	N/A	-101	N/A	-54	N/A
12/31/2016	N/A	-96	N/A	-41	N/A
9/30/2016	N/A	-94	N/A	-38	N/A
6/30/2016	N/A	-87	N/A	-78	N/A
3/31/2016	N/A	-84	N/A	-70	N/A
12/31/2015	N/A	-82	N/A	-69	N/A
9/30/2015	N/A	-78	N/A	-64	N/A
6/30/2015	N/A	-71	N/A	-58	N/A
3/31/2015	N/A	-60	N/A	-54	N/A
12/31/2014	N/A	-83	N/A	-40	N/A
9/30/2014	N/A	-73	N/A	-33	N/A
6/30/2014	N/A	-64	N/A	-27	N/A
3/31/2014	N/A	-59	N/A	-18	N/A
12/31/2013	N/A	-18	N/A	-17	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von ARAV über der Sparquote liegt (2.2%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von ARAV schneller wachsen werden als der Markt US

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von ARAV in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von ARAV schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von ARAV schneller wachsen werden als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ARAV in 3 Jahren voraussichtlich hoch sein wird

Aravive Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 51%

Consensus revenue estimates increase by 95%

Consensus revenue estimates fall by 35%

Consensus revenue estimates increase by 44%

Price target decreased to US$9.80

Consensus forecasts updated

Recent updates

Aravive Files Form 15

Aravive, Inc. Announces Board and Committee Resignations

Aravive, Inc. Notifies Nasdaq of its Intention to File a Form 25 on or About January 29, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Aravive Receives Letters from Nasdaq Regarding Non-Compliance with Minimum Market Value of its Listed Securities, Minimum Market Value of its Publicly Held Shares, and Minimum Closing Bid Price Requirement

Aravive, Inc., Annual General Meeting, Oct 02, 2023

Consensus revenue estimates decrease by 51%

Aravive, Inc. Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer

Consensus revenue estimates increase by 95%

Aravive, Inc. Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma

Consensus revenue estimates fall by 35%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aravive, Inc. Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian

Aravive Inc. Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC

Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 44%

Price target decreased to US$9.80

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aravive, Inc. announced that it has received $41.559988 million in funding from BVF Partners L.P., Eshelman Ventures, LLC, The Invus Group, LLC, and other investors

Consensus forecasts updated

Aravive, Inc. announced that it expects to receive $41.55547 million in funding from BVF Partners L.P., Eshelman Ventures, LLC, The Invus Group, LLC

Consensus forecasts updated

Aravive Receives Third Development Milestone from 3D Medicines

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Consensus revenue estimates increase by 10%

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aravive Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Aravive Q2 GAAP EPS misses, revenue beats

Aravive, Inc., Annual General Meeting, Sep 22, 2022

Aravive, Inc. Appoints Robert B. Geller as Chief Medical Officer

Aravive appoints Robert Geller as CMO

Price target decreased to US$18.20

Aravive, Inc. Appoints Rudy Howard as Chief Financial Officer

Aravive, Inc. Presents Updated Clinical Data At Asco Showing Continued Best-In-Class Potential of Batiraxcept in Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Consensus revenue estimates fall by 25%

We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

High number of new directors

Consensus forecasts updated

Price target decreased to US$19.75

Aravive, Inc. Announces Positive Updated Data and New Biomarker Data from Phase 1b Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting

Aravive, Inc. Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

High number of new directors

Aravive, Inc. announced that it has received $10.000001 million in funding from Eshelman Ventures, LLC

Aravive, Inc. announced that it expects to receive $10.000001 million in funding from Eshelman Ventures, LLC

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive Inc Announces First Patient Dosed in Phase 1B/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma

Consensus revenue estimates increase to US$7.34m

Aravive, Inc.(NasdaqGS:ARAV) dropped from Russell Microcap Growth Index

Aravive Announces Positive Initial Results from Phase 1b Portion of the Phase1b/2 Study of AVB-500

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Consensus revenue estimates increase to US$4.10m

Aravive, Inc. Plans to Investigate AVB-500 in Clinical Trial as First-Line Treatment for Pancreatic Cancer

Aravive EPS beats by $0.01, misses on revenue

Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer

Aravive shares rise after dosing first patient in late-stage ovarian cancer study

Insider exercised options to buy US$318k worth of stock.

Consensus revenue estimates increase to US$3.11m

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Full year 2020 earnings released: US$1.93 loss per share (vs US$1.57 loss in FY 2019)

Aravive, Inc. Announces Updated Data from Its Phase 1B Trial Evaluating Avb-500 in Platinum Resistant Ovarian Cancer

Aravive, Inc. Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma

New 90-day high: US$6.85

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Dr. Ray Tabibiazar Announces to Step Down from the Aravive Board of Directors